{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:38:38Z","timestamp":1779881918489,"version":"3.53.1"},"reference-count":34,"publisher":"Impact Journals, LLC","issue":"33","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2015,10,27]]},"DOI":"10.18632\/oncotarget.5300","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T21:54:23Z","timestamp":1443563663000},"page":"34732-34744","source":"Crossref","is-referenced-by-count":8,"title":["Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment"],"prefix":"10.18632","volume":"6","author":[{"given":"Xiaorong","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Radiology, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"},{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Ackerstaff","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuqiu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligang","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Shandong Key Laboratory of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung Tsung","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Current address: Department of Anesthesiology, E-Da Hospital, Yanchau District, Kaohsiung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A.","family":"Koutcher","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Clifton","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria C.","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA"},{"name":"Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,9,23]]},"reference":[{"key":"1","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents","volume":"59","author":"Elliott","year":"1999","journal-title":"Cancer Res"},{"key":"2","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1081\/CNV-120030218","article-title":"Development of the proteasome inhibitor Velcade (Bortezomib)","volume":"22","author":"Kauffman","year":"2004","journal-title":"Cancer Invest"},{"key":"3","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Kuter","year":"2003","journal-title":"N Engl J Med"},{"key":"4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/annonc\/mdl316","article-title":"A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150","volume":"18","author":"Eisenhauer","year":"2007","journal-title":"Ann Oncol"},{"key":"5","first-page":"9","article-title":"Cancer statistics","volume":"64","author":"Jemal","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"6","first-page":"806506","article-title":"The role of proteasome inhibition in nonsmall cell lung cancer","volume":"2011","author":"Raez","year":"2011","journal-title":"J Biomed Biotechnol"},{"key":"7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CAD.0b013e328342fedb","article-title":"Antiproteasomal agents in rectal cancer","volume":"22","author":"Cusack","year":"2011","journal-title":"Anticancer Drugs"},{"key":"8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2012.04.002","article-title":"Targeting the Ubiquitin Proteasome System in Solid Tumors","volume":"49","author":"Steve","year":"2012","journal-title":"Semin Hematol"},{"key":"9","doi-asserted-by":"crossref","first-page":"5526","DOI":"10.1158\/1078-0432.CCR-05-0081","article-title":"A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer","volume":"11","author":"Moore","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/annonc\/mdp390","article-title":"Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"21","author":"Parker","year":"2010","journal-title":"Ann Oncol"},{"key":"11","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/JTO.0b013e31824de2fa","article-title":"Phase-I\/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Perez-Soler","year":"2012","journal-title":"J Thorac Oncol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/0008-5472.CAN-06-2722","article-title":"Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors","volume":"67","author":"Hedley","year":"2007","journal-title":"Cancer Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/nrc3064","article-title":"Targeting hypoxia in cancer therapy","volume":"11","author":"Hay","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrc3183","article-title":"HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression","volume":"12","author":"Simon","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"15","doi-asserted-by":"crossref","first-page":"9323","DOI":"10.1158\/0008-5472.CAN-08-2873","article-title":"Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways","volume":"68","author":"Koumenis","year":"2008","journal-title":"Cancer Res"},{"key":"16","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood-2006-06-032664","article-title":"Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib","volume":"109","author":"Ferrero","year":"2007","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/978-1-4614-7411-1_31","article-title":"Tumor oxygenation: an appraisal of past and present concepts and a look into the future: Arisztid G.B Kov\u00e0ch Lecture","volume":"789","author":"Vaupel","year":"2013","journal-title":"Adv Exp Med Biol"},{"key":"18","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1593\/neo.81360","article-title":"Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia","volume":"11","author":"Koutcher","year":"2009","journal-title":"Neoplasia"},{"key":"19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00109-011-0805-8","article-title":"Bortezomib represses HIF-1alpha protein expression and nuclear accumulation by inhibiting both PI3K\/Akt\/TOR and MAPK pathways in prostate cancer cells","volume":"90","author":"Liakos","year":"2012","journal-title":"J Mol Med (Berl)"},{"key":"20","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1158\/0008-5472.CAN-08-4103","article-title":"Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression","volume":"69","author":"McConkey","year":"2009","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood-2007-11-120576","article-title":"Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1","volume":"111","author":"Park","year":"2008","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1096\/fasebj.14.1.65","article-title":"Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells","volume":"14","author":"Konerding","year":"2000","journal-title":"FASEB J"},{"key":"23","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.yexcr.2009.11.005","article-title":"Bortezomib induces autophagic death in proliferating human endothelial cells","volume":"316","author":"Ferrero","year":"2010","journal-title":"Exp Cell Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1078-0432.CCR-13-1950","article-title":"HIF-1alpha of bone marrow endothelial cells implies relapse and drug resistance in patients with multiple myeloma and may act as a therapeutic target","volume":"20","author":"Guarini","year":"2014","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.2174\/092986711798184316","article-title":"Proteasome inhibitors and modulators of angiogenesis in multiple myeloma","volume":"18","author":"Ferrero","year":"2011","journal-title":"Curr Med Chem"},{"key":"26","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/mrm.20149","article-title":"Assessment of tumor blood perfusion by high-resolution dynamic contrast-enhanced MRI: a preclinical study of human melanoma xenografts","volume":"52","author":"Rofstad","year":"2004","journal-title":"Magn Reson Med"},{"key":"27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.mri.2008.07.021","article-title":"Examining the acute effects of cediranib (RECENTIN, AZD2171) treatment in tumor models: a dynamic contrast-enhanced MRI study using gadopentate","volume":"27","author":"Wedge","year":"2009","journal-title":"Magn Reson Ima"},{"key":"28","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1158\/1535-7163.MCT-09-0239","article-title":"The relationship among tumor architecture, pharmacokinetics, pharmacodynamics, and efficacy of bortezomib in mouse xenograft models","volume":"8","author":"Kupperman","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 1","key":"29","first-page":"S164","article-title":"Perfusion MRI in the early clinical development of antivascular drugs: decorations or decision making tools?","author":"Padhani","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"30","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.18632\/oncotarget.2163","article-title":"Targeting hypoxia-inducible factor-1alpha (HIF-1alpha) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab","volume":"5","author":"Hess","year":"2014","journal-title":"Oncotarget"},{"key":"31","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1097\/JTO.0b013e31824de2fa","article-title":"Phase-I\/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancer","volume":"7","author":"Perez-Soler","year":"2012","journal-title":"J Thoracic Oncol"},{"key":"32","doi-asserted-by":"crossref","first-page":"8597","DOI":"10.1158\/0008-5472.CAN-08-0677","article-title":"Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers","volume":"68","author":"Li","year":"2008","journal-title":"Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1158\/1535-7163.MCT-14-0697","article-title":"Targeting Three Distinct HER2 Domains with a Recombinant Antibody Mixture Overcomes Trastuzumab Resistance","volume":"14","author":"Kragh","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"34","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mrm.1910330408","article-title":"Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography","volume":"33","author":"Lorenz","year":"1995","journal-title":"Magn Reson Med"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:20:51Z","timestamp":1599610851000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.5300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,23]]},"references-count":34,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2015,10,27]]}},"alternative-id":["5300","26416246"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.5300","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,23]]}}}